RxSight Securities Fraud Lawsuit: Lead Plaintiff Deadline Set for September 22, 2025
ByAinvest
Saturday, Sep 20, 2025 9:18 am ET1min read
RXST--
The lawsuit claims that throughout the class period, RxSight made materially false and misleading statements, including overstating the demand for its products and failing to disclose significant declines in sales and utilization. As a result, investors purchased RxSight common stock at artificially inflated prices, leading to financial losses when the true details emerged.
Investors who purchased RxSight securities during the class period may be eligible for compensation without payment of fees or costs through a contingency fee arrangement. Rosen Law Firm has extensive experience in securities class actions and shareholder derivative litigation, having secured hundreds of millions of dollars for investors in past cases.
To participate in the lawsuit, investors can visit [Rosen Law Firm's website](https://rosenlegal.com/submit-form/?case_id=42362) or contact Phillip Kim, Esq., at 866-767-3653 or email case@rosenlegal.com. Investors who wish to serve as lead plaintiff must move the court no later than September 22, 2025. Until a class is certified, investors are not represented by counsel unless they retain one.
RxSight investors with losses over $100K have until Sept. 22, 2025, to lead a securities fraud lawsuit. The law firm Rosen Law Firm is representing investors and has experience in securities class actions and shareholder derivative litigation. The lawsuit claims that RxSight made false and misleading statements about its field organization, customer adoption, and utilization across the installed base. Investors who purchased RxSight securities between May 7, 2024, and July 8, 2025, may be eligible for compensation without payment of fees or costs.
Investors who purchased RxSight, Inc. (NASDAQ: RXST) securities between May 7, 2024, and July 8, 2025, and suffered losses of over $100,000 are urged to participate in a securities fraud class action lawsuit. The deadline to lead the lawsuit is September 22, 2025. The Rosen Law Firm is representing investors in this matter, which alleges that RxSight made false and misleading statements about its field organization, customer adoption, and utilization across the installed base.The lawsuit claims that throughout the class period, RxSight made materially false and misleading statements, including overstating the demand for its products and failing to disclose significant declines in sales and utilization. As a result, investors purchased RxSight common stock at artificially inflated prices, leading to financial losses when the true details emerged.
Investors who purchased RxSight securities during the class period may be eligible for compensation without payment of fees or costs through a contingency fee arrangement. Rosen Law Firm has extensive experience in securities class actions and shareholder derivative litigation, having secured hundreds of millions of dollars for investors in past cases.
To participate in the lawsuit, investors can visit [Rosen Law Firm's website](https://rosenlegal.com/submit-form/?case_id=42362) or contact Phillip Kim, Esq., at 866-767-3653 or email case@rosenlegal.com. Investors who wish to serve as lead plaintiff must move the court no later than September 22, 2025. Until a class is certified, investors are not represented by counsel unless they retain one.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet